Among patients participating in the pivotal SENSCIS trial that compared nintedanib with placebo for SSc-ILD, more than four times as many patients assigned to the active drug developed signs of ...

Ofev (nintedanib) and cost. ... The drug’s cost with and without insurance can depend on several factors, such as whether Ofev has a savings program you’re eligible for.

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous SSc and interstitial lung disease, according to data derived from Allanore Y, et al. Rheumatology. 2023 ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung ...

Future Oncol. 2014;10(2):219-231. There are several limitations to this study. The use of a composite end point such as PFR has not been validated in trials of CRPC. It also requires that patients ...

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in ...

New data from Boehringer Ingelheim support the potential use of nintedanib in children ... regulatory applications will be submitted to the European Medicines Agency and U.S. Food and Drug ...

The authors plan to study other types of cancers, such as liver and oral cancer, using the same system. “This fibrin/Matrigel co-culture system could be useful for evaluating the effects of drug ...